VERZENIO
Drug timelines are a Plus or Pro feature.
84 regulatory and trial events tracked for VERZENIO, covering 2017-09-28 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas [Phase 1, Phase 2]